Cite
HARVARD Citation
Gullo, G. et al. (2019). Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial. Therapeutic advances in medical oncology. p. . [Online].